The aim of the current work was to develop stable formulation of rizatriptan benzoate in the form of floating matrix tablet, in combination with two different polymers hydroxy propyl methyl cellulose (HPMC K4M) and Eudragit RLPO. The Rizatriptan benzoate in a form of gastro retentive floating sustained release dosage forms, which provides enhanced bioavailability. In the present study rizatriptan benzoate controlled release tablet were prepared with the help of the direct compression method, using sodium bicarbonate and citric acid as the gas forming agent. Rizatriptan benzoate is an antimigraine drug. The plasma half-life of drug is approximately 2-3 Hrs. The tablets were evaluated for the pre and post compression parameters such as FTIR spectroscopy, differential scanning calorimetry, weight variation, thickness, friability, hardness, drug content, in-vitro buoyancy studies, in-vitro dissolution studies and stability studies and results were within the limits. The in-vitro dissolution studies were carried out in a USP type-II apparatus in 0.1 N HCl. Among all the formulations (F1 to F9) prepared, batch F3 was the best formulation which showed buoyancy lag time 18 sec and the tablet remained buoyant for > 12 h. The in-vitro data is fitted in to different kinetic models and the best-fit was achieved with the higuchi model. Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) were performed to identify the physicochemical interaction between Rizatriptan benzoate and the polymer. The in-vitro drug release from the tablets was found to have 75.81±0.16% to 99.43±0.18% for 12 hr. Stability study was performed on the optimized formulation F3 at 40°C/ 75% RH for 3 months.
Loading....